We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, Eli Lilly Defend Emergency Clearance for COVID-19 Antibody Drug
FDA, Eli Lilly Defend Emergency Clearance for COVID-19 Antibody Drug
Efficacy questions are swirling about the 700-mg dose of Eli Lilly’s COVID-19 antibody treatment bamlanivimab that just this week received Emergency Use Authorization (EUA) from the FDA.